Association of oral microbiome and pancreatic cancer: a systematic review and meta-analysis

Mengyao Yuan, Ying Xu and Zhimin Guo

Abstract

Background: Oral microbiota reported to be associated with pancreatic diseases, including pancreatic cancer. However, the association of oral microbiome and pancreatic cancer has not been reviewed systematically.

Objectives: To systematically investigate the association between the oral microbiome and pancreatic cancer risk.

Design: A systematic review and meta-analysis.

Data Sources and Methods: Systemic searches were conducted using PubMed, Medline, Cochrane Library, and Embase databases without any language restriction from conception to August 29, 2020. The studies that evaluated the association of oral microbiome and pancreatic cancer risk were included in this meta-analysis.

Results: The six included studies encompassed a total of 863 pancreatic cancer cases and 906 controls. Four studies reported the overall oral microbiome in pancreatic cancer cases. A total of 12–17 species/clusters were correlated with pancreatic cancer. Three studies reported the odds ratios (ORs) or relative abundance of several oral microbiomes pieces/clusters, and the majority were associated with pancreatic cancer.

Conclusions: Overall, this study supports the hypothesis of associations of variations of patients’ oral microbiota to pancreatic cancer. Nonetheless, due to all included studies were conducted in USA or Europe, additional original studies and meta-analysis particular studies from other countries are essential for an in-depth investigation into the role of oral bacteria in pancreatic cancer.

Keywords: oral microbiome, oral bacteria, pancreatic cancer, association, meta-analysis
case–control study. However, the association of oral microbiome and pancreatic cancer has not been reviewed systematically. The previously published literature on this topic facilitates a robust and persuasive systematic review and meta-analysis that can provide specific evidence on the association of oral microbiome and pancreatic cancer. In this study, we systemically evaluated the association between the oral microbiome and pancreatic cancer risk by summarizing the relevant studies.

**Methods**

**Literature search**

To search the potential studies, PubMed, Medline, Cochrane Library, and Embase were employed without any language restriction from initiation to 29 August 2020. The individual and joint keywords used to search the potential literature were as follows: ‘microbiota’ OR ‘microbiome’ OR ‘microbiome’ AND ‘pancreatic cancer’ OR ‘pancreatic carcinoma’. To include the literature, we also browsed the bibliographies of all relevant studies and reviews for additional eligible studies. Google Scholar was also searched for studies citing relevant articles. This current study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines.

**Eligibility criteria**

Studies that addressed the topic of the effects of the oral microbiome and pancreatic cancer were included. The inclusion criteria were as follows: (1) study population that was diagnosed as pancreatic cancer without restriction to histological types, such as adenocarcinoma, acinar cell carcinoma, intraductal papillary-mucinous carcinoma or anaplastic carcinoma, etc.; (2) cohort or case–control studies that focused on the association of oral microbiome and pancreatic cancer; (3) necessary data that could be extracted from original studies; (4) studies published in English; and (5) the study from the same institution providing detailed information or newly published article was selected if the study population was reported in duplicate.

Case reports, letters, reviews, comments, conference abstracts, and studies conducted in animal models or experiments in vitro, studies in languages other than English, and studies that were not available were excluded from this meta-analysis.

**Data extraction**

All studies retrieved from the above-mentioned datasets were evaluated independently by two authors (Zhimin Guo and Mengyao Yuan). Needed information was extracted by the two reviewers independently using a standardized form. The discrepancy was discussed with a third author (Ying Xu) and the consensus was reached on all the items. For all included studies, the following information was extracted: the name of first author, year of publication, and study design, characteristics of participants patient and/or control characteristics, disease characteristics, and results on the oral microbiome.

**Quality scoring of studies**

The quality of the included studies was assessed independently by two authors with the Quality Assessment and Validity Tool for Newcastle-Ottawa Scale (NOS), a procedure to independently assess the methodological quality of meta-analysis of observational studies. The NOS for grading observational studies was based on three factors: the selection of participants, comparability of each group, and exposure of factors. A study can be awarded 2–9 points. Studies awarded 0–2 points were defined as poor quality, 3–5 points as medium, and 6–9 as high quality.

**Statistical analysis**

Weighted mean correlations or odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were pooled using inverse variance methods with random effects. The standard heterogeneity was assessed using a statistic. For the \( P \geq 50\% \) and \(<50\%\), the heterogeneity was deemed with and without significant heterogeneity, respectively. When significant heterogeneity was observed, we sequentially excluded the included studies to explore the source of the heterogeneity. The publication bias was assessed by Begg’s rank correlation and Egger’s weighted regression methods. Statistical analyses and the Begg’s and Egger’s tests were performed using Comprehensive Meta-Analysis (version 3.0, Biostat Inc.). \( p \) Values of <0.05 indicated statistical significance.
Results

Study selection
The study selection flowchart is illustrated in Figure 1. The systematic literature search yielded 379 studies by the search strategy, and 172 were excluded due to duplication. Based on the above inclusion and exclusion criteria, 177 abstracts and titles were reviewed initially. It is worth noting that 13 studies were excluded due to necessary information cannot be extracted, which included authors assessed oral microbiome in multiple types of cancers and did not report exact information on pancreatic cancer. After retrieving 30 full-length manuscripts, ultimately, six articles\textsuperscript{12,13,19-22} were included for data extraction and meta-analysis.

Study characteristics
The six studies encompassed a total of 863 pancreatic cancer cases and 906 controls. All the included studies were retrospective case–control studies, published between 2012 and 2019, and the sample size ranged from 30 to 911. 4/6 studies were conducted in the United States,\textsuperscript{12,13,20,21} one in Sweden,\textsuperscript{22} and one in other European countries (including 10 European countries: Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom).\textsuperscript{19} The controls were healthy individuals, and one study matched the case and control be age and sex.\textsuperscript{19} The characteristics of the included studies are shown in Tables 1 and 2. Supplemental Table 1 presents microbes that were significant in each included study.

Quality assessment of studies
According to the scale of the published quality assessment and validity tool for correlational studies, three studies were assessed as moderate quality and 3 (7 points) as high quality (\geq \text{8 points}). The detailed scores for each included study are shown in Table 3.

Assessment of oral microbiome
One study detected the antibody of the oral microbiome using plasma samples and the presence of antibodies using an immunoblot array with respect to 16S rRNA. Gene amplification and sequencing were used for the other five studies. Total bacterial 16S DNA gene copy number was quantified using the TaqMan quantitative polymerase chain reaction (qPCR) or real-time PCR.

Overall oral microbiome
Four studies reported the overall oral microbiome in pancreatic cancer cases. The study by Farrell et al.\textsuperscript{12} observed 16 species/clusters, including Streptococcus (3 species/groups), Prevotella (4 species/groups), Campylobacter (4 species/groups), Granulicatella (2 species), Atopobium (1 species), and Neisseria (2 species). For the study conducted by Michaud et al.,\textsuperscript{19} 25 preselected oral bacteria, including Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, had a two-fold higher risk of pancreatic cancer than individuals with lower levels of these antibodies (OR: 2.14; 95% CI: 1.05–4.36; >200 ng/ml versus \leq 200 ng/ml). 12 and 17 bacterial phyla were observed for the studies by Torres \textit{et al.}\textsuperscript{20} and Fan \textit{et al.}\textsuperscript{21}, respectively.

Oral microbiome and pancreatic cancer cases
Two of six included studies reported the correlation between the abundance of \textit{Leptotrichia} and
| Study included       | Country | Study design | PD cases | Controls |
|---------------------|---------|--------------|----------|----------|
|                      |         |              | $n$      |          |
| Farrell et al.$^{12}$ | USA     | Case–control | 28       | Healthy controls 28 |
| Michaud et al.$^{19}$ | Europe  | Case–control | 40       |          |
| Torres et al.$^{20}$  | USA     | Case–control | 8        | Healthy controls 22 |
| Olson et al.$^{21}$   | USA     | Case–control | 34       | Healthy controls 58 |
| Fan et al.$^{13}$     | USA     | Case–control | 36       | Healthy controls 37 |
| Gaiser et al.$^{22}$  | Sweden  | Case–control | 27       | Healthy controls 21 |

Age (means ± SD, years), % of males

| Selection of controls | $n$ | Age (mean ± SD, years) | % of males | Tool for 16S sequences |
|-----------------------|-----|------------------------|------------|------------------------|
| Healthy controls      | 28  | 65.1 ± 10.1            | 64.28      | QIIME                  |
| Age- and sex-matched healthy controls | 40  | 57.8 ± 7.9             | 47.80      | QIIME                  |
| Healthy controls      | 22  | NA                     | 54.55      | QIIME                  |
| Healthy controls      | 58  | NA                     | 39.66      | MOTHUR                 |
| Healthy controls      | 37  | 63.8                   | 57.14      | QIIME                  |
| Healthy controls      | 21  | 71 (46–83)             | 4.76       | QIIME                  |

NA, not available; QIIME, the Quantitative Insights Into Microbial Ecology; SD, standard deviation; USA, United States of America.

| Table 2. Characteristics of included pancreatic cancer cases. |
|--------------------------------------------------------------|
| Study included       | Sample size of pancreatic cancer cases | Diagnosis of pancreatic cancer | Samples | Microbiology assessment |
|----------------------|----------------------------------------|-------------------------------|---------|-------------------------|
| Farrell et al.$^{12}$ | 28                                     | Pathology                     | Saliva samples | 16S rRNA gene and real-time quantitative PCR |
| Michaud et al.$^{19}$ | 405                                    | Pathology                     | Blood samples | Antibody                |
| Torres et al.$^{20}$  | 8                                      | Pathology                     | Saliva samples | 16S rRNA gene and quantitative PCR sequence analysis |
| Olson et al.$^{21}$   | 34                                     | Pathology                     | Saliva samples | 16S rRNA gene and TaqMan quantitative PCR |
| Fan et al.$^{13}$     | 361                                    | Pathology                     | Saliva samples | 16S rRNA gene and TaqMan quantitative PCR |
| Gaiser et al.$^{22}$  | 27                                     | Pathology                     | Saliva samples | 16S rRNA gene and multiplexed and barcoded sequences |

NA, not available; PCR, polymerase chain reaction.
pancreatic cancer. When the results were pooled, the \( r \) value for the correlation was 0.749, with the corresponding 95% CI as 0.197–0.940 with no significant heterogeneity \( (I^2 = 22\%) \). The forest plot is shown in Figure 2.

Three studies\(^{11,13,20}\) reported the ORs or relative abundance of several oral microbiomes species/clusters, such as *Firmicutes*, *Proteobacteria*, *Bacilli*, *Gammaproteobacteria*, *Betaproteobacteria*, *Lactobacillales*, *Pasteurellales*, *Neisseriales*, *Streptococcaceae*, *Pasteurellaceae*, *Neisseriaceae*, *Streptococcus*, *Hemophilus*, and *Neisseria*. As the results can be pooled when at least two studies reported one group of microbiome, we therefore summarized four groups of microbiomes, including *Fusobacteria*, *Bacteroidetes*, *Streptococcus*, and *Pasteurellaceae*. The pooled results of ORs for *Fusobacteria*, *Bacteroidetes*, *Streptococcus*, and *Pasteurellaceae* are presented in Figure 3. *Fusobacteria* showed a slightly significant association with pooled OR as 0.94 (95% CI: 0.89–0.99). No heterogeneity was observed for each pooled process \( (I^2 < 25\%) \).

Of the included studies, one divided the samples into the identification and verification of bacterial candidates by real-time qPCR. When combining the two bacterial strains (*N. elongata* and *S. mitis*), an improved receiver operating characteristic plot area under the curve was seen as 0.90 (95% CI: 0.78–0.96, \( p < 0.0001 \)) with sensitivity and specificity for distinguishing pancreatic cancer and healthy subjects as 96.4% and 82.1%, respectively.

**Publication bias**

No potential publication bias was detected among the included trials, according to Begg's
rank correlation analysis and Egger’s weighted regression analysis (pooled process for the combination of Fusobacteria, n = 3, p > 0.05).

**Discussion**
To the best of our knowledge, although several reviews have been published in this topic, the current study is the first meta-analysis on the association of pancreatic cancer and oral microbiome. In this meta-analysis, six studies with a total of 863 pancreatic cancer cases and 906 controls were included. This study supported the hypothesis of associations between variations of patients’ oral microbiota and pancreatic cancer.

Previous study has reported the mechanism of microbiota-related tumor progression by two domains: inflammation and pro-tumorigenic immunomodulation in the tumor microenvironment. Chronic inflammation and infections are increasingly identified as a vital factor in the development of cancers. A recent meta-analysis concluded that periodontitis was associated with pancreatic cancer, even after adjusting for several risk factors. Several previous studies reported that gut microbiota dysbiosis, bacterial translocation, and inflammation were strongly linked with several pancreatic disorders, including pancreatic cancer. Although this is the first meta-analysis to systemically analyze the association of oral microbiome with pancreatic cancer, the results support the existing literature and warrant further investigation.

**Figure 2.** Summarized correlations of abundance of *Leptotrichia* and pancreatic cancer.

**Figure 3.** Summarized ORs of increase or decrease in oral microbiome for pancreatic cancer. ORs, odds ratio.
bacterial pathogens with pancreatic cancer risk, there is evidence supporting this finding. Some key pathogens among oral bacteria, such as the *P. gingivalis* and *A. actinomycetemcomitans*, are involved in the initiation of periodontal disease and tooth loss. Recent studies also assessed the associations of oral microbiome with pancreatic cancer, such as the study conducted by Petrick et al. which reported no associations were observed. Another study conducted in China found *Leptotrichia* might be associated with pancreatic cancer specifically for patients in Sichuan Province, southwest China. A previous study observed the strong association between periodontal disease and tooth loss prospectively, also the association with increased risk of pancreatic cancer. Five studies from the six included studies used saliva samples to perform gene sequencing analysis. One study measured antibodies to oral bacteria in pre-diagnosis blood samples.

The bacterial assessment in pancreatic tumor development has been investigated by several approaches, including molecular and culture methods. The two approaches were seen similarities to oral microbiota. Bacteria that has been demonstrated could reach pancreatic tissues by dissemination. The study that used pre-diagnostic bloods were able to minimize reverse causation. However, antibody levels might be influenced by drug use which may lead to lower sensitivity. Whether local oral microbiota infection without entering the bloodstream could potentially lead to systemic chronic inflammation or neoplasia is currently under intense focus. The immune system of our bodies recognizes the microbiota infection by the overexpression of a family of membrane receptors, known as Toll-like receptors (TLRs). The process of recognition of microbial components by TLRs can initiate signal transduction pathways. Thus, upregulated genes are launched in innate immune responses that effectuate the further development of antigen-specific acquired immunity. In addition to the effects on immune cells, these TLRs also act on specific epithelial cells, including cancer cells, which promote their phenotypic transformation. Besides the above-mentioned pathogenic mechanism, accumulating evidence also indicates ‘mouth–gut axis’ in the context of pathogenesis of gastrointestinal diseases. Kitamoto et al. conducted a study on amassed oral pathobionts and reported that oral inflammation promotes gut inflammation by supplying the gut with both colitogenic pathobionts and pathogenic T cells.

In the past decades, various studies reported that moderate inflammatory reaction was protective against tumorigenesis and excessive inflammatory response was reportedly to be a promoter to carcinogenesis in several types of cancers, including pancreatic cancer. In some cases, the tumorigenic process does not demonstrate the results of the activities of a specific organism but rather the result of an instability in the composition of the bacterial communities or dysbiosis. Recently, with the application of the next-generation sequencing, neoplastic inflammatory microenvironment also observed had effect in the oral microbiome. Pushalkar et al. reported enhanced the enrichments of some species and significantly decreased the abundance levels of some others.

In our study, both positive and negative associations of oral microbiota were seen with pancreatic cancer, which indicates that oral microbiota positively associated with pancreatic cancer may promote cancerization. Negative oral microbiota may be caused by wide genetic diversity, such as *Leptotrichia*. The impact of *Leptotrichia* in human health remains unclear and was deemed as an opportunistic pathogen. Further studies are needed to investigate this relationship, and disentangle the complex role of immune response in pancreatic carcinogenesis. However, the observed association between pancreatic cancer and oral microbiome in our study may not prove causality. It is possible that the oral microbiome change is a consequence of pancreatic cancer occurrence, rather than be a factor for predisposing to pancreatic cancer. The conclusion that patients’ oral microbiota is associated with pancreatic cancer which provides novel evidence to evaluate the specificity of microbial biomarkers. In clinical settings, the screening for pancreatic cancer is challenging. Early small pancreatic cancers, also known as PanIN stages, need to be detected. Moreover, the phenotypically similar chronic pancreatitis, a benign pancreatic disease, needs to be differentiated from pancreatic cancer. Thus, in future, a bacterial biomarker based on patients’ oral microbiota might benefit pancreatic cancer cases.

When interrupting the findings of the current study, the limitations should be kept in mind. First, all included studies were conducted in the Western
countries and all the participants were Caucasian population. The representativeness of the study population might be weakened and therefore more studies from other countries are needed. Third, the limited number of included studies also reported various oral microbiome and statistical methods were employed. These could impede future investigations with respect to these studies. Fourth, in our study, we observed an association of oral microbiome and pancreatic cancer. However, due to the nature of the observed study design, the increase or decrease in oral microbiome may not causally related to pancreatic cancer. Fifth, none of the included studies provided stage of pancreatic cancer and that might be a potential source of bias. Sixth, potential language bias might exist because our literature searches only considered the articles published in English. Seventh, publication bias cannot be assessed for all the analyses as a limited number of studies were included.

In conclusion, in the current meta-analysis, we first and systematically assessed the correlations between the oral microbiome and pancreatic cancer and the pooled results based on six studies from three different regions or countries. Next, we observed the slight correlation between the oral microbiome and pancreatic cancer. However, as all the six studies were conducted in western countries (the United States and Europe) and a weak scientific background of the correlation, additional studies are essential to validate and understand disease progression in pancreatic cancer. Limited by the small number of included studies, original studies and meta-analysis with a large sample size from different counties are needed to verify the current conclusion.

Declaration

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contribution(s)

Mengyao Yuan: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Ying Xu: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Zhimin Guo: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Acknowledgements

None.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the Achievement Transformation Project of the First Hospital of Jilin University (Nos. JDYYZH-1902025, JDYYGH2019013, 2020-ZL-05), and the Scientific Research Foundation of the Education Department of Jilin Province (No. JJKH20201087KJ).

Competing interests

The authors declare that there is no conflict of interest.

Availability of data and materials

Not applicable.

ORCID iD

Zhimin Guo https://orcid.org/0000-0002-2800-5589

Supplemental material

Supplemental material for this article is available online.

References

1. Davoodi SH, Malek-Shahabi T, Malekshahi-Moghadam A, et al. Obesity as an important risk factor for certain types of cancer. Iran J Cancer Prev 2013; 6: 186–194.

2. Smetana K Jr., Lacina L, Szabo P, et al. Ageing as an important risk factor for cancer. Anticancer Res 2016; 36: 5009–5017.
3. Cao Y and Giovannucci EL. Alcohol as a risk factor for cancer. *Semin Oncol Nurs* 2016; 32: 325–331.

4. De Koster E, Buset M, Fernandes E, et al. Helicobacter pylori: the link with gastric cancer. *Eur J Cancer Prev* 1994; 3: 247–257.

5. Ellison SA. Oral bacteria and periodontal disease. *J Dent Res* 1970; 49: 198–202.

6. Leishman SJ, Do HL and Ford PJ. Cardiovascular disease and the role of oral bacteria. *J Oral Microbiol* 2010; 2: 5781.

7. Gomes-Filho IS, Passos JS and Seixas da Cruz S. Respiratory disease and the role of oral bacteria. *J Oral Microbiol* 2010; 2: 5811.

8. Gholizadeh P, Eslami H, Yousefi M, et al. Role of oral microbiome on oral cancers: a review. *Biomed Pharmacother* 2016; 84: 552–558.

9. Peters BA, Wu J, Pei Z, et al. Oral microbiome composition reflects prospective risk for esophageal cancers. *Cancer Res* 2017; 77: 6777–6787.

10. Lim Y, Totsika M, Morrison M, et al. Oral microbiome: a new biomarker reservoir for oral and oropharyngeal cancers. *Theranostics* 2017; 7: 4313–4321.

11. Goral V. Pancreatic cancer: pathogenesis and diagnosis. *Asian Pac J Cancer Prev* 2015; 16: 5619–5624.

12. Farrell JJ, Zhang L, Zhou H, et al. Variations of oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. *Cancer Causes Control* 2017; 28: 959–969.

13. Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. *Gut* 2013; 62: 1764–1770.

14. Torres PJ, Fletcher EM, Gibbons SM, et al. Characterization of the salivary microbiome in patients with pancreatic cancer. *PeerJ* 2015; 3: e1373.

15. Olson SH, Satagopan J, Xu Y, et al. The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. *Cancer Causes Control* 2017; 28: 959–969.

16. Bracci PM. Oral health and the oral microbiome in pancreatic cancer: an overview of epidemiological studies. *Cancer J* 2017; 23: 310–314.

17. Karpinski TM. Role of oral microbiota in cancer development. *Microorganisms* 2019; 7: 20.

18. Vallianou N, Kounatidis D, Christodoulatos GS, et al. Mycobiome and cancer: what is the evidence? *Cancers* (Basel) 2021; 13: 3149.

19. Bellotti R, Speth C, Adolph TE, et al. Micro- and mycobiota dysbiosis in pancreatic ductal adenocarcinoma development. *Cancers* (Basel) 2021; 13: 3431.

20. Shacter E and Weitzman SA. Chronic inflammation and cancer. *Oncology (Williston Park)* 2002; 16: 217–226, 229.

21. Kamp DW, Shacter E and Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. *Oncology (Williston Park)* 2011; 25: 400–410, 413.

22. Maisonneuve P, Amar S and Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. *Ann Oncol* 2017; 28: 985–995.

23. Pagliari D, Saviano A, Newton EE, et al. Gut microbiota-immune system crosstalk and pancreatic disorders. *Mediators Inflamm* 2018; 2018: 7946431.

24. Costalonga M and Herzberg MC. The oral microbiome and the immunobiology of periodontal disease and caries. *Immunol Lett* 2014; 162: 22–38.
32. Petrick JL, Wilkinson JE, Michaud DS, et al. The oral microbiome in relation to pancreatic cancer risk in African Americans. Br J Cancer 2022; 126: 287–296.

33. Wei AL, Li M, Li GQ, et al. Oral microbiome and pancreatic cancer. World J Gastroenterol 2020; 26: 7679–7692.

34. Hujoel PP, Drangsholt M, Spiekerman C, et al. An exploration of the periodontitis-cancer association. Ann Epidemiol 2003; 13: 312–316.

35. Brook I and Frazier EH. Microbiological analysis of pancreatic abscess. Clin Infect Dis 1996; 22: 384–385.

36. Swidsinski A, Schlien P, Pernthaler A, et al. Bacterial biofilm within diseased pancreatic and biliary tracts. Gut 2005; 54: 388–395.

37. Fawkner-Corbett D, Simmons A and Parikh K. Microbiome, pattern recognition receptor function in health and inflammation. Best Pract Res Clin Gastroenterol 2017; 31: 683–691.

38. Michallet MC, Meylan E, Ermolaeva MA, et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 2008; 28: 651–661.

39. Rich AM, Hussaini HM, Parachuru VP, et al. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol 2014; 5: 464.

40. Garrett WS. Cancer and the microbiota. Science 2015; 348: 80–86.

41. Mueller MM. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer 2006; 42: 735–744.

42. Feller L, Altini M and Lemmer J. Inflammation in the context of oral cancer. Oral Oncol 2013; 49: 887–892.

43. Farrow B and Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002; 10: 153–169.

44. Pushalkar S, Mane SP, Ji X, et al. Microbial diversity in saliva of oral squamous cell carcinoma. FEMS Immunol Med Microbiol 2011; 61: 269–277.

45. Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol 2010; 192: 5002–5017.

46. Miyoshi H, Kano M, Kobayashi S, et al. Diffuse pancreatic cancer mimicking autoimmune pancreatitis. Intern Med 2019; 58: 2523–2527.